Abstract
Donafenib, an oral multi-kinase inhibitor that targets Raf/MEK/ERK, VEGFR, PDGFR, has shown potent efficacy and well-tolerated safety profile in patients with progressive locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) in a phase II study. The DIRECTION study aims to evaluate the efficacy and safety of donafenib and initiated when there was no available TKI for Chinese RAIR-DTC patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
